Personalized Cancer Vaccines in Combination Therapies: Current Status and Future Prospects.

Personalized cancer vaccines represent a promising advancement in cancer immunotherapy, designed to target tumor-specific mutations unique to individual patients. By stimulating a tailored immune response, these vaccines aim to enhance antitumor immunity while minimizing off-target effects. However, cancer is a complex disease, and single-modality treatments often face challenges such as immune evasion and tumor heterogeneity. To address these limitations, personalized cancer vaccines are increasingly being explored in combination with other therapeutic strategies, including immune checkpoint inhibitors, cytokine therapies, oncolytic viruses, and traditional chemotherapies. This review provides a comprehensive overview of the current status of personalized cancer vaccines, focusing on their development, clinical trials, and early outcomes. It also discusses the synergistic potential of combination therapies, offering insights into how these strategies could overcome immunosuppressive tumor microenvironments and improve patient outcomes. Finally, we explore future prospects, addressing challenges such as vaccine production, patient selection, and regulatory frameworks to outline the path forward for the successful integration of personalized vaccines into standard oncological care.